AbbVie

News

NICE backs pump-based Parkinson’s drug from AbbVie

A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

CVS Health launches private label biosimilars unit

CVS Health has made a move on the US biosimilars category with the launch of Cordavis, a new business unit that will work with other drugmakers to bring private-label bios

News

Samsung seeks 'interchangeable' label for Humira biosimilar

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

NICE backs pump-based Parkinson’s drug from AbbVie

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

FDA starts swift review of Regeneron’s CD20 bispecific

CVS Health launches private label biosimilars unit

Samsung seeks 'interchangeable' label for Humira biosimilar

AbbVie nears EU nod for DLBCL drug epcoritamab

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks